Fill/Finish Lessons Learned from COVID-19

Contract development and manufacturing organizations (CDMOs) specializing in sterile fill/finish were key to the success of the COVID-19 vaccine roll-out, delivering aseptic manufacturing capacity and expertise. But can CDMOs do better in the future? What lessons can be learned to further speed up sterile processing for the next pandemic?

Reflecting on the past 24 months

The development and commercialization of effective vaccines to tackle the COVID-19 pandemic happened at an unprecedented pace and on an unparalleled scale. Billions of doses of a range of approved
vaccines have now been administered to patients across the globe. Millions more continue to be manufactured to provide boosters capable of tackling new variants in an effort to prevent a repeat of the events of spring 2020.

Vaccine spending worldwide was higher in 2021 than any previous year (1). Total cumulative spending for the COVID-19 vaccine program is forecast to hit $157 billion by 2025 (2).

The past two years have demonstrated that it is possible for the pharmaceutical industry to achieve new heights of speed and efficiency in development and manufacturing, all while maintaining optimum levels of quality and safety.

Read this article in the BioPharm International Partnerships for Outsourcing eBook.

About the author

Roberto Raffaele Addamo is head of Commercial, Sterile Fill & Finish at Recipharm.

Article details

BioPharm International
eBook: Partnerships for Outsourcing
May 2023
Pages: 24–27

Citation

When referring to this article, please cite it as Addamo, RR. Fill/Finish Lessons Learned from COVID-19. BioPharm International, Partnerships for Outsourcing eBook May 2023.

IM Imagery - Stock.adobe.com